Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody ®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application (MAA) for epcoritamab submitted by AbbVie The...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news